1577P Optimizing the management of PARP inhibitors in clinical practice: Results of a DELPHI French consensus

Selle, F.; Scotté, F.; Boffa, J-J.; Etienne, G.; Angelergues, A.; Augereau, P.; Berton-Rigaud, D.; Dielenseger, P.; Fabbro, M.; Falandry, C.; Follana, P.; Gladieff, L.; Lobbedez, F. Joly; Kurtz, J.E.; Matta, C.; Reynier, M.A. Mouret; Schmitt, A.; Marjollet, C.; Floquet, A.

doi:10.1016/j.annonc.2022.07.1670

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A new Delphi consensus amongst a French multidisciplinary steering committee considered the use of G-CSFs to treat neutropenia induced by poly (ADP-ribose) polymerase inhibitors, which are currently used in ovarian and breast cancer therapies. 32 The committee did not recommend the use of G-CSFs for this indication at the present time, due to the lack of efficacy data. 32 However, further research into this application may be warranted.…”

Section: Emerging Topics In Granulocyte-colony Stimulating Factor Pro...mentioning

confidence: 95%

See 1 more Smart Citation

The Role of Granulocyte-Colony Stimulating Factor Biosimilars for Supportive Cancer Care: A Year in Review

Moir

2023

EMJ

View full text Add to dashboard Cite

This year-in-review article provides insights into clinical updates relating to granulocyte-colony stimulating factor (G-CSF) biosimilars research presented at five key congresses in 2022. These include the American Society of Clinical Oncology (ASCO) 55th Annual Meeting (3rd–7th June 2022, Chicago, Illinois, USA), European Society for Medical Oncology (ESMO) Congress (9th–13th September 2022, Paris, France), ESMO Asia Congress (2nd–4th December 2022, Singapore), San Antonio Breast Cancer Symposium (SABCS; 6th–10th December 2022, Texas, USA), and American Society of Hematology (ASH) 64th Annual Meeting and Exposition (10th–13th December 2022, New Orleans, Louisiana, USA). Alongside reviewing the current research presented at these key congresses, with a focus on the use of G-CSF agents and biosimilars in patients undergoing treatment for breast, colorectal, and gynaecological cancers, this article provides an overview of current guidelines on the use of G-CSF in supportive cancer care to manage chemotherapy-induced febrile neutropenia and explores trends in G-CSF biosimilars research.

show abstract

Section: Emerging Topics In Granulocyte-colony Stimulating Factor Pro...mentioning

confidence: 95%

“…32 The committee did not recommend the use of G-CSFs for this indication at the present time, due to the lack of efficacy data. 32 However, further research into this application may be warranted.…”

Section: Emerging Topics In Granulocyte-colony Stimulating Factor Pro...mentioning

confidence: 95%

The Role of Granulocyte-Colony Stimulating Factor Biosimilars for Supportive Cancer Care: A Year in Review

Moir

2023

EMJ

View full text Add to dashboard Cite

show abstract

1577P Optimizing the management of PARP inhibitors in clinical practice: Results of a DELPHI French consensus

Cited by 1 publication

References 0 publications

The Role of Granulocyte-Colony Stimulating Factor Biosimilars for Supportive Cancer Care: A Year in Review

The Role of Granulocyte-Colony Stimulating Factor Biosimilars for Supportive Cancer Care: A Year in Review

Contact Info

Product

Resources

About